About this Research Topic
In the past 30 years, diabetes has been a major cause of mortality in public. According to the report of World Health Organization, the global prevalence of diabetes among adults rose from 4.7% in 1980 to 8.5% in 2014, and there was a 5% increase in premature death from diabetes between 2000 and 2016. Diabetes has been associated with microvascular disease and twofold higher risk of heart failure, sarcopenia and atherosclerotic cardiovascular disease, leading to an increased risk of mortality. The pathological mechanisms underlying the relationships have been mediated by increased inflammation, glycosylation, oxidative stress, insulin resistance, mitochondrial dysfunction and endothelial dysfunction. Numerous clinical trials demonstrated that some state-of-art pharmacological therapy such as ACEI or ARB, HMG-CoA reductase inhibitors and SGLT-2 inhibitors for diabetes may have cardio-protection and survival benefits. However, the beneficial mechanisms related to pharmacological therapy in diabetes have not been fully understood.
The purpose of this research topic is to understand the advances in knowledge concerning the state-of-art pleiotropic pharmacological effects including ACEI or ARB, HMG-CoA reductase inhibitors and SGLT-2 inhibitors on diabetes and the prognosis in animal and human studies. This research will be important for obtaining more evidence-based evidence of the beneficial effect of the state-of–art medical treatment in diabetes and the future applications of research may lead to an improvement in the outcome of clinical care for diabetes.
We invite articles that examine the state-of-art pharmacological mechanisms on cardiac remodelling (diabetic cardiomyopathy), sarcopenia, inflammation, atherosclerosis and the clinical prognosis in diabetes. Accordingly, we welcome articles which investigate how to refine therapeutic strategies for diabetes. We expect to receive a range of article types such as Original Research, Reviews articles, Mini-Reviews, Perspectives and more aimed at assessing the state-of-art pleiotropic pharmacological effects on cardiovascular and muscular systems in diabetes and evaluating the clinical prognosis. The work based essentially on basic or clinical data will not be considered positively in the favor of multidisciplinary efforts in the logic “from bench to bed – and return". We welcome all article types and expect submissions relating to, but not limited to, the following topics:
• The effect of ACEI or ARB on sarcopenia in diabetes, on cardiac remodelling in diabetes, or on cytokines in diabetes;
• The effect of HMG-CoA reductase inhibitors on sarcopenia in diabetes, on cardiac remodelling in diabetes, or on proinflammatory cytokines in diabetes;
• The effect of SGLT-2 inhibitors on sarcopenia in diabetes, on cardiac remodelling in diabetes, or on proinflammatory cytokines in diabetes;
• Clinical prognosis of using state-of-art pharmacological therapy in a diabetes population-based study.
Keywords: ACEI/ARB, diabetic cardiomyopathy, HMG-CoA reductase inhibitors, sacropenia, SGLT-2 inhibitors
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.